StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report published on Wednesday. The firm issued a hold rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $19.00 price objective on shares of Oncternal Therapeutics in a research report on Friday, May 31st.

Oncternal Therapeutics Price Performance

NASDAQ ONCT opened at $8.78 on Wednesday. The firm has a market cap of $26.00 million, a PE ratio of -0.71 and a beta of 1.38. Oncternal Therapeutics has a one year low of $5.57 and a one year high of $13.14. The stock’s 50 day simple moving average is $8.72 and its 200 day simple moving average is $8.79.

Oncternal Therapeutics (NASDAQ:ONCT) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($2.83) EPS for the quarter, beating analysts’ consensus estimates of ($2.88) by $0.05. The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.18 million. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. During the same period last year, the company earned ($4.00) EPS. As a group, equities analysts expect that Oncternal Therapeutics will post -10.78 earnings per share for the current year.

Insider Buying and Selling at Oncternal Therapeutics

In related news, Director Robert James Wills purchased 3,086 shares of Oncternal Therapeutics stock in a transaction dated Monday, April 8th. The shares were acquired at an average cost of $8.96 per share, for a total transaction of $27,650.56. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $89,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned about 0.94% of Oncternal Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.